Voloridge Investment Management
AUTL icon

Voloridge Investment Management’s Autolus Therapeutics AUTL Stock Holding History

Voloridge Investment Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121,035
Closed -$439K – 1174
2024
Q3 		$439K Sell
121,035
-27,542
-19% -$110K ﹤0.01% 1095
2024
Q2 		$517K Sell
148,577
-364,270
-71% -$1.57M ﹤0.01% 1122
2024
Q1 		$3.27M Buy
+512,847
New +$3.2M 0.01% 744

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Voloridge Investment Management's AUTL Position: Q4 2024 in Review

Voloridge Investment Management sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 121,035 shares — an estimated $439K sold.

Voloridge Investment Management first reported a position in AUTL in Q1 2024 and held it in 3 quarters. The position peaked at $3.27M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • Voloridge Investment Management reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 121,035 Autolus Therapeutics shares in Q4 2024, an estimated $439K.
  • Voloridge Investment Management first reported a position in Autolus Therapeutics in Q1 2024 and held it in 3 quarters.
  • Voloridge Investment Management's Autolus Therapeutics position peaked at $3.27M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on Voloridge Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.